MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fphar.2024.1502791

Медицинская библиотека · Frontiers in pharmacology · 2025

Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database.

Wang Bojing, Huang Shu, Li Shiqi, Deng Yaqi, Li Ziyan, Wang Yizhou, Shi Xiaomin, Zhang Wei, Shi Lei, Wang Xiaohong, Tang Xiaowei

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Statins, as an important class of lipid-lowering drugs, play a key role in the prevention and treatment of cardiovascular diseases. However, with their widespread use in clinical practice, some adverse events have gradually emerged. In particular, the hepatotoxicity associated with statins use has become one of the clinical concerns that require sufficient attention.

METHODS

In this study, we conducted a comprehensive and detailed analysis of the hepatotoxicity of statins based on the data of the US Food and Drug Administration Adverse Event Reporting System database from the first quarter (Q1) of 2004 to the Q1 of 2024 and used Reporting Odds Ratios and Empirical Bayes Geometric Mean to mine the signal of adverse events.

RESULTS

In this study, hepatic disorder related seven statins all exhibited positive signals. Through signal mining, we identified a total of 14,511 cases of adverse events associated with hepatic disorder caused by these statin drugs, with atorvastatin, simvastatin, and rosuvastatin occurring at a higher rate. A total of 148 positive signals related to adverse events of hepatic disorder were captured. Autoimmune hepatitis and drug-induced liver injury both presented positive signals across multiple statin drugs. Notably, atorvastatin had the most significant signal strength in cholestatic pruritus and bilirubin conjugation abnormal. Fluvastatin also showed notable signal strength in autoimmune hepatitis, while simvastatin had a relatively weaker signal strength for hepatic enzyme increased.

CONCLUSION

This study discovered specific adverse event signal values, revealing potential hepatotoxic risks associated with the use of statin drugs. The results provide an important reference for the safe clinical use of drugs, help to improve the understanding of the safety of statins, and also provide a scientific basis for clinicians to make more accurate and safe decisions when making treatment plans.

Для цитирования: Wang Bojing, Huang Shu, Li Shiqi, Deng Yaqi, Li Ziyan, Wang Yizhou, Shi Xiaomin, Zhang Wei, Shi Lei, Wang Xiaohong, Tang Xiaowei. Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database.. Frontiers in pharmacology. 2025. DOI: 10.3389/fphar.2024.1502791.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.